Meds & Biologics
You responded well to your biologic at first. Symptoms settled, labs improved, and you started to feel like yourself again. But now, months or years later, things are shifting. The urgency is creeping back, the fatigue is harder to shake, and you are wondering whether your Crohn's biologic stopped working. This experience, known clinically as loss of response, is one of the most common challenges in long-term Crohn's management. It does not mean you have run out of options. It means it is time for a structured conversation with your gastroenterologist about what comes next.
How Common Is Biologic Loss of Response?
Loss of response to biologics in Crohn's disease is well-documented and far from unusual. Studies estimate that 10 to 30 percent of patients never achieve adequate response during induction, while 23 to 46 percent who do respond initially will lose that response over time. The annual risk of secondary loss of response sits at roughly 5 to 20 percent per year for anti-TNF agents like infliximab and adalimumab. These numbers make biologic loss of response IBD one of the most frequently encountered treatment hurdles. Understanding that this is a recognized pattern can help reduce the anxiety that comes with feeling your Crohn's treatment not working the way it once did.
Why Biologics Lose Effectiveness
The most common cause of loss of response with anti-TNF therapies is immunogenicity, where your immune system produces antibodies against the drug itself. These anti-drug antibodies can neutralize the medication or speed up how quickly your body clears it, leaving levels too low to suppress inflammation. Other factors include changes in disease behavior, increased inflammatory burden, or shifts in the dominant pathway driving your inflammation. Sometimes what looks like loss of response is actually a separate issue (an infection, a stricture, or overlapping irritable bowel symptoms). Your GI team will want to rule these out before making changes to your regimen.
The Role of Therapeutic Drug Monitoring
Before switching medications, most gastroenterologists will recommend therapeutic drug monitoring Crohn's patients through a blood test measuring two things: the trough level of your biologic and the presence of anti-drug antibodies. The ACG's 2025 guidelines support TDM-based decision making for secondary loss of response. The general framework:
If your drug level is low with no anti-drug antibodies, dose optimization (increasing dose or shortening interval) is the first move.
If your drug level is low due to high anti-drug antibodies, switching to another biologic (often within the same class) is recommended.
If your drug level is adequate but symptoms persist, the mechanism of action may no longer fit your disease, and switching to a different class is the next step.
This approach avoids unnecessary medication changes when a dose adjustment might restore effectiveness, and avoids prolonged exposure to a drug your body is actively working against.
Dose Optimization Before Switching
When TDM reveals low drug levels without significant antibody formation, dose optimization is a reasonable first strategy. This might mean increasing the milligram dose per infusion or reducing time between doses. Research on dose escalation shows that a meaningful proportion of patients can recapture response through these adjustments alone, sparing them the disruption of switching biologics Crohn's disease patients often worry about. Your gastroenterologist may recheck levels after the adjustment to confirm concentrations have reached a therapeutic range.
Switching Biologics: Within Class or Across Class
When your current biologic is no longer effective, the decision of what to try next depends on why it failed. Patients who developed anti-drug antibodies to one anti-TNF may still respond to another, since antibodies are often drug-specific. For patients whose disease continued despite adequate drug levels (a mechanistic failure), switching biologics Crohn's disease treatment to a different class is more logical. Options include IL-23 inhibitors (risankizumab, guselkumab), IL-12/23 inhibitors (ustekinumab), integrin inhibitors (vedolizumab), and small molecules like upadacitinib. Recent network meta-analyses suggest risankizumab ranks highly for both induction and maintenance remission in anti-TNF-exposed patients.
Building Your Case With Symptom Data
One of the most practical things you can do when you suspect your Crohn's biologic stopped working is document exactly what is happening and when it started. Your gastroenterologist will want to know the timeline: when symptoms returned, how they compare to your pre-treatment baseline, and whether the change was gradual or sudden. This history directly influences whether your doctor orders therapeutic drug monitoring, schedules imaging, or moves toward a medication change.
If your biologic may be losing effect, your symptom trend is critical evidence. Track daily with Aidy so you and your GI can see exactly when things started changing. Having that data ready transforms the conversation from guesswork into a concrete, evidence-informed discussion about your next steps.